In Vivo Pharmacodynamics of β-Lactams/Nacubactam against Carbapenem-Resistant and/or Carbapenemase-Producing <i>Enterobacter cloacae</i> and <i>Klebsiella pneumoniae</i> in Murine Pneumonia Model

Carbapenem-resistant Enterobacterales (CRE) and carbapenemase-producing Enterobacterales (CPE) have become global threats. CRE− and CPE− derived infections have been associated with high mortality due to limited treatment options. Nacubactam is a β-lactamase inhibitor and belongs to the new class of...

Full description

Bibliographic Details

Published in:	Antibiotics
Main Authors:	Mao Hagihara, Hideo Kato, Toshie Sugano, Hayato Okade, Nobuo Sato, Yuichi Shibata, Daisuke Sakanashi, Jun Hirai, Nobuhiro Asai, Hiroyuki Suematsu, Yuka Yamagishi, Hiroshige Mikamo
Format:	Article
Language:	English
Published:	MDPI AG 2021-09-01
Subjects:	aztreonam cefepime meropenem nacubactam carbapenemase-producing Enterobacterales carbapenem-resistant Enterobacterales
Online Access:	https://www.mdpi.com/2079-6382/10/10/1179